Which adverse reactions are commonly reported with Adjuvanted Trivalent Influenza Vaccine Seqirus in adults aged 65 years and older?

For Adjuvanted Trivalent Influenza Vaccine Seqirus, relevant clinical-study data in adults aged 65 years and older identify injection-site pain (16–32%), fatigue (10–16%) and headache (11–12%) as commonly reported reactions, with most solicited reactions mild or moderate and resolving within three days.